Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Key Executives
Name
Title
Richard R. DeLuca
Executive VP/President, Divisional
Robert M. Davis
CEO/Chairman of the Board/Director/President
Betty D. Larson
Executive VP/Other Executive Officer
Sanat Chattopadhyay
Executive VP/President, Divisional
Chirfi Guindo
Chief Marketing Officer/Senior VP, Divisional
Jennifer Zachary
Executive VP/General Counsel
Caroline A. Litchfield
CFO/Executive VP
David Michael Williams
Chief Information Officer/Executive VP/Other Executive Officer